Compare iShares Self-Driving EV and Tech (IDRV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Merck & Co., Inc. — how do they compare? iShares Self-Driving EV and Tech trades at $35.9, while Merck & Co., Inc. trades at $125.83 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares Self-Driving EV and Tech pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $129.52 |
52-Week Low | $32.13 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% with a bearish technical outlook as moving averages signal strong selling pressure. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026, providing income potential amid market volatility.
The stock faces headwinds from technical weakness and competitive EV market dynamics. Upside depends on broader EV adoption trends and company-specific execution, while risks include regulatory changes and economic pressures. Investors should weigh the bearish signals against long-term sector growth opportunities.
MRK trades at $125.85, down 1.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30 suggesting 9% upside. Recent earnings have consistently beaten expectations, with Q1 2026 loss narrower than forecast. The company maintains strong profitability with a 73.91% gross margin and 18.97% ROE, while actively expanding its pipeline through acquisitions like Terns Pharmaceuticals.
Outlook remains positive driven by earnings beats and strategic M&A, but risks include rising debt levels and patent expirations. The stock offers a dividend yield with upcoming payment, supported by institutional accumulation. Valuation multiples are elevated, requiring sustained growth to justify current levels amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
